Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

alpha crop protection pty ltd - diflufenican - suspension concentrate - diflufenican anilide/aniline-nicotinanilide active 500.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

herbs of gold pty ltd - alpha lipoic acid -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pregabalin, quantity: 150 mg - capsule - excipient ingredients: maize starch; purified talc; hyprolose; titanium dioxide; purified water; iron oxide yellow; erythrosine; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pregabalin alphapharm (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pregabalin alphapharm (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pregabalin, quantity: 75 mg - capsule - excipient ingredients: hyprolose; purified talc; maize starch; titanium dioxide; purified water; iron oxide yellow; erythrosine; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pregabalin alphapharm (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pregabalin alphapharm (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pregabalin, quantity: 25 mg - capsule - excipient ingredients: maize starch; purified talc; hyprolose; titanium dioxide; purified water; iron oxide yellow; erythrosine; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pregabalin alphapharm (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pregabalin alphapharm (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pregabalin, quantity: 300 mg - capsule - excipient ingredients: maize starch; hyprolose; purified talc; titanium dioxide; purified water; iron oxide yellow; erythrosine; gelatin; sodium lauryl sulfate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pregabalin alphapharm (pregabalin) is indicated for the treatment of neuropathic pain in adults.,pregabalin alphapharm (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1 g in 50 ml - glassia is an alpha1 -proteinase inhibitor (human), indicated for chronic augmentation and maintenance therapy in individuals with clinically evident emphysema due to severe hereditary deficiency of alpha1 -pi, also known as alpha1 -antitrypsin (aat) deficiency. limitations of use : - the effect of augmentation therapy with glassia or any alpha1 -pi product on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. - clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with glassia are not available. - glassia is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. glassia is contraindicated in: - immunoglobulin a (iga) deficient patients with antibodies against iga. - individuals with a history of anaphylaxis or other severe systemic reaction to alpha1 -pi products. risk summar

United States - English - NLM (National Library of Medicine)

grifols usa, llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - prolastin® -c liquid is an alpha1 -proteinase inhibitor (human) (alpha1 -pi) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). limitations of use - the effect of augmentation therapy with any alpha1 -pi, including prolastin-c liquid, on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.    - clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with prolastin-c liquid are not available. - prolastin-c liquid is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. prolastin-c liquid is contraindicated in: - iga deficient patients with antibodies against iga, due to the risk of severe hypersensitivity. - patients with a history of anaphylaxis or other sever

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; colloidal anhydrous silica; povidone; poloxamer; croscarmellose sodium; sodium lauryl sulfate; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - tadalafil, quantity: 5 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; povidone; microcrystalline cellulose; sodium lauryl sulfate; poloxamer; colloidal anhydrous silica; lactose; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - tadalafil alphapharm is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males